Acta Med. 2014, 57: 30-33

https://doi.org/10.14712/18059694.2014.6

DENOSUMAB ASSOCIATED WITH BONE DENSITY INCREASE AND CLINICAL IMPROVEMENT IN A LONG-TERM HEMODIALYSIS PATIENT. CASE REPORT AND REVIEW OF THE LITERATURE

Sylvie Dusilová Sulkováa,b, Jiří Horáčekc, Roman Šafránekb,d, Petr Gorune, Ondřej Viklickýf, Vladimír Paličkag

aDepartment of Internal Medicine II, Charles University, Faculty of Medicine and University Hospital, Hradec Králové, Czech Republic
bHemodialysis Centre, University Hospital Hradec Kralové, Czech Republic
cDepartment of Internal Medicine IV, Charles University, Faculty of Medicine and University Hospital, Hradec Králové, Czech Republic
dDepartment of Internal Medicine III, Charles University, Faculty of Medicine and University Hospital, Hradec Králové, Czech Republic
eHemodialysis centre BBraun Avitum, Ústí nad Orlicí, Czech Republic
fDepartment of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
gDepartment of Clinical Biochemistry, Charles University, Faculty of Medicine and University Hospital, Hradec Králové, Czech Republic

References

1. Cummings SR, San Martin J, McClung MR, et al: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 33–41. <https://doi.org/10.1056/NEJMoa0809493>
2. Block GA, Bone HG, Fang L et al: A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012; 27: 1471–1479. <https://doi.org/10.1002/jbmr.1613> <PubMed>
3. McCormick BB, Davis J, Burns KD: Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis 2012; 60: 626–628. <https://doi.org/10.1053/j.ajkd.2012.06.019>
4. Torregrosa JV: Dramatic increase in parathyroid hormone and hypocalcemia after denosumab in a kidney transplanted patient. Clin Kidney J 2013; 6: 122; doi 10:1093/ckj/sfs158 <https://doi.org/10.1093/ckj/sfs158> <PubMed>
5. Ivanov P, Khedr M: Prolonged hypocalcemia following a single dose of 60 ug denosumab in two patients with CKD4/5 on cinacalcet treatment for tertiary hyperparathyroidism. Clin Kidney J 2013; doi:10.1093/ckj/sft014 <https://doi.org/10.1093/ckj/sft014> <PubMed>
6. Ungprasert O, Cheungpasitporn W, Srivali N, et al: Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am J Emergency Med 2013; 31: 756e1–756e2.
7. Talreja DB: Severe hypocalcemia following a single injection of denosumab in a patient with renal impairment. J Drug Assessment 2012; 1: 33–36. <https://doi.org/10.3109/21556660.2012.668504> <PubMed>
8. Agarwal M, Csongradi E, Koch AC: Severe symptomatic hypocalcemia after denosumab administration in an end-stage renal disease patient on peritoneal dialysis with controlled secondary hyperparathyroidism. British J Med Medical Research 2013; 3: 1398–1406. <https://doi.org/10.9734/BJMMR/2013/2989>
9. Westenfeld R, Ketteler M, Brandenburg VM: Anti-RANKL therapy – implications for the bone-vascular-axis in CKD? Denosumab in post-menopausal women with low bone mineral density Nephrol Dial Transplant 2006: 21: 2075–2077.
10. Fukagawa M, Kazama JJ, Shigematsu T et al: Skeletal resistance to PTH as a basic abnormality underlying uremic bone disease. Am J Kidney Dis 2001; 38: 152–155. <https://doi.org/10.1053/ajkd.2001.27426>
11. Albalate M, la Piedra C, Fernandez C et al: Association between phosphate removal and markers of bone turnover in haemodialysis patients. Nephrol Dial Transplant 2006; 21: 1626–1632. <https://doi.org/10.1093/ndt/gfl034>
12. Gonnelli S, Montagnani A, Caffarelli C, et al. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis. J Endocrinol Invest 2005; 28: 534–539. <https://doi.org/10.1007/BF03347242>
13. Kazama JJ, Kato H, Sato T, et al: Circulating osteoprotegerin is not removed through haemodialysis membrane. Nephrol Dial Transplant 2002; 17: 1860–1861. <https://doi.org/10.1093/ndt/17.10.1860>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive